No headlines found.
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Globe Newswire (Fri, 10-Jan 7:00 AM ET)
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Globe Newswire (Thu, 14-Nov 4:05 PM ET)
Globe Newswire (Thu, 7-Nov 4:05 PM ET)
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Spero Therapeutics trades on the NASDAQ stock market under the symbol SPRO.
As of February 7, 2025, SPRO stock price declined to $0.83 with 99,480 million shares trading.
SPRO has a beta of 1.41, meaning it tends to be more sensitive to market movements. SPRO has a correlation of 0.14 to the broad based SPY ETF.
SPRO has a market cap of $45.25 million. This is considered a Sub-Micro Cap stock.
Last quarter Spero Therapeutics reported $13 million in Revenue and -$.32 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.04.
In the last 3 years, SPRO traded as high as $10.90 and as low as $.68.
The top ETF exchange traded funds that SPRO belongs to (by Net Assets): VTI, VXF, IWC.
SPRO has underperformed the market in the last year with a price return of -43.9% while the SPY ETF gained +23.6%. SPRO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.6% and -4.7%, respectively, while the SPY returned +2.5% and -1.0%, respectively.
SPRO support price is $.82 and resistance is $.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRO shares will trade within this expected range on the day.